SUBSCRIBE
SUBSCRIBE

Merck & Co.

AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
  • 2024 Best Places to Work
NEWS
BioMidwest
Merck & Co., Inc. (Jobs)'s New AIDS Drug Has Promise -- If It Isn’t Too Pricey
October 11, 2007
 · 
1 min read
GlaxoSmithKline (Jobs) ‘s Cervarix Priced on Par with Merck & Co., Inc. (Jobs) ‘s Gardasil in UK
October 2, 2007
 · 
1 min read
GlaxoSmithKline (Jobs) Vs Merck & Co., Inc. (Jobs) as Cervarix Goes on Sale in Europe
September 28, 2007
 · 
1 min read
Pharm Country
Merck & Co., Inc. Set to Donate Cancer Vaccine Doses
September 27, 2007
 · 
1 min read
Drug Development
Crucell N.V. Says it Not to Blame for Merck & Co., Inc.'s HIV Flop
September 25, 2007
 · 
1 min read
Drug Development
Cervical Vaccine Protects Against More Virus Strains Than Previously Thought
September 20, 2007
 · 
1 min read
Load More
JOBS
IN THE PRESS
Press Releases
KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)
March 2, 2026
 · 
19 min read
Press Releases
WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
March 2, 2026
 · 
19 min read
Press Releases
KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer
March 2, 2026
 · 
19 min read
Press Releases
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
March 2, 2026
 · 
19 min read
Press Releases
Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer
February 26, 2026
 · 
2 min read
Press Releases
FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis
February 26, 2026
 · 
8 min read
Press Releases
Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026
February 26, 2026
 · 
19 min read
Press Releases
Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge
February 24, 2026
 · 
8 min read
Press Releases
Merck to Participate in the TD Cowen 46th Annual Health Care Conference
February 24, 2026
 · 
3 min read
Press Releases
Merck Evolves Human Health Operating Structure to Support Portfolio Execution
February 23, 2026
 · 
5 min read
Load More